Puerto Rican plant to boost US supplies of heparin
This article was originally published in Scrip
Executive Summary
US FDAapproval for APP Pharmaceuticals's Puerto Rican plant to manufacture three heparin products should help ensure the uninterrupted and safe supply of heparin to the US, says the company. APP is currently the sole supplier of therapeutic heparin vials to the US after contamination problems occurred there earlier this year, says the company's CEO, Tom Silberg. Nine products are currently manufactured at the company's Puerto Rican plant, including doxycycline, azithromycin and diphenhydramine.